S-1 - Humacyte, Inc. (0001818382) (Filer)

8-K - Humacyte, Inc. (0001818382) (Filer)

8-K - Humacyte, Inc. (0001818382) (Filer)

25-NSE - Alpha Healthcare Acquisition Corp. (0001818382) (Subject)

8-K - Alpha Healthcare Acquisition Corp. (0001818382) (Filer)

425 - Alpha Healthcare Acquisition Corp. (0001818382) (Subject)

8-K - Alpha Healthcare Acquisition Corp. (0001818382) (Filer)

10-Q - Alpha Healthcare Acquisition Corp. (0001818382) (Filer)

EFFECT - Alpha Healthcare Acquisition Corp. (0001818382) (Filer)

424B3 - Alpha Healthcare Acquisition Corp. (0001818382) (Filer)

Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, and all other proposals presented at AHAC's special shareholder's meeting held on August 24, 2021. AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC votes cast at the meeting. AHAC plans to file the results of the

In addition to the Company's eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the U.S.Video testimonial features patient who experienced a traumatic leg injury and received the HAV to restore blood flow to her crushed limb DURHAM, N.C., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U

Appoints proven commercial leader B.J. Scheessele as Chief Commercial OfficerIn-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing systemCompany's proprietary modular manufacturing systems can produce an estimated 40,000+ vessels annually in current facility when scaled up DURHAM, N.C., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced advancements in its commercial operations with the appointment of B.J. Scheessele as Chief Commercial Officer. In addition, Human Acellul

Nominees bring depth and diversity of scientific, commercial and financial experience to Board NEW YORK and DURHAM, N.C., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced the nominees who will stand for election/reelection to its Board of Directors during the August 24, 2021, AHAC special shareholder's meeting to vote on the proposed business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. The post-combination Board will be comprised of 11 directors, including seven independen

Data demonstrate biovascular pancreas may have the potential to provide an effective and safe method for pancreatic islet cell transplantation for the treatment of type 1 diabetes Data published in the Journal of Tissue Engineering DURHAM, N.C., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announced laboratory and preclinical data demonstrating the potential to engineer a biovascular pancreas as a method to transplant pancreatic islet cells for the long-term treatment of type 1 diabetes have been published in the Journal of Tissue Engineering. The man

Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc. to be held August 24, 2021, at 10:00 a.m. EDTShareholders as of the close of business on July 21, 2021, should vote their AHAC shares, no matter how many shares they ownAHAC recommends all shareholders vote "FOR" all proposals at the special shareholder meeting NEW YORK and DURHAM, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (NASDAQ:AHAC) ("AHAC"), a special purpose acquisition company, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") and set a date of August 24, 2021, for its

DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announces that Laura Niklason, M.D., Ph.D., Chief Executive Officer, delivered an invited presentation on laboratory and preclinical findings and notable criteria for engineering functional air sacs in the lungs, which support the potential to create engineered lung tissue organ, at the virtual Janelia R3 – Replace, Repair, Regenerate Planning Workshop. Janelia is a Howard Hughes Medical Institute pioneering research center that empowers an integrated team of scientists to pursue a small numb

Partnership expanded to include vascular trauma repair outside of the United States.Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives.Fresenius Medical Care is a leading participant in fully committed PIPE financing transaction. DURHAM, N.C., June 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, announces the expansion of the strategic collaboration between Fresenius Medical Care, the world’s largest provider of dialysis products and services. Under the expanded collaboration, Fres

DURHAM, N.C., June 10, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a fireside chat on regenerative medicine at the Cowen 6th Annual FutureHealth Conference taking place virtually on June 16, 2021, at 10 a.m. EDT. The webcast will be available for replay for 30 days following the presentation and can be accessed at www.Humacyte.com. On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purp

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

4 - Humacyte, Inc. (0001818382) (Issuer)

Benchmark initiated coverage of Alpha Healthcare with a rating of Buy and set a new price target of $18.00

The Benchmark Company initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $18.00

Lake Street initiated coverage of Alpha Healthcare Acquisition Corp. with a rating of Buy and set a new price target of $20.00

Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under "HUMA" and "HUMAW" on August 27, 2021Company well-positioned to deliver on promise of regenerative tissue HAV technology for initial indications in vascular trauma, AV access and peripheral arterial diseaseCombined company will be led by Laura Niklason, M.D., Ph.D., Founder, President & CEO, and current executive teamKathleen Sebelius appointed Chair of the Board of DirectorsHumacyte to commemorate milestone by ringing Nasdaq closing bell on Monday, August 30, 2021 DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform

SC 13G - Humacyte, Inc. (0001818382) (Subject)

SC 13D - Humacyte, Inc. (0001818382) (Subject)

SC 13D - Humacyte, Inc. (0001818382) (Subject)

SC 13G - Alpha Healthcare Acquisition Corp. (0001818382) (Subject)